SuZhou, China,Aug. 20,2024 –GeneQuantum Healthcare announced today that, effective July 26, 2024,  it has joined Johnson & Johnson Innovation _JLABS @ Shanghai as the 100th resident company. It is a significant step forward for GeneQuantum to accelerate innovations to make an impact for patients around the world. By leveraging JLABS global network and resources, GeneQuantum Healthcare aims to accelerate the development of the next generation of antibody-drug conjugates (ADCs) with wider therapeutic windows and offer higher affordability through its proprietary bioconjugation technology.

Since its establishment in 2013, GeneQuantum Healthcare has focused on key technological innovations and novel ADC development. Over the course of more than a decade, GeneQuantum Healthcare has independently created three general core technology platforms within a global patent portofolio: an enzymatic site-specific conjugation platform, a stable linker-payload platform and an intelligent manufacturing platform. On this foundation, a series of next-generation ADCs with significant potential have been developed. Currently, the innovative ADC products GQ1001, GQ1005, and GQ1010 have entered the clinical stage.

GeneQuantum Healthcare has built a complete end-to-end process solution system from drug discovery to commercial production. iScreener, the world's first high-throughput intelligent preparation and screening platform, leads the way in advancing ADC drug discovery from "by design" to "by screen". This has greatly improved the efficiency and success rate of drug development. iConjugator, an intelligent conjugation manufacturing platform, seamlessly integrates the conjugation process with the antibody manufacturing process, achieving a disruptive breakthrough in the production of ADC drugs within monoclonal antibody workshops, with obvious commercial cost advantages.

Dr. Gang Qin, Founder and Chairman of GeneQuantum, said, “we are very pleased to join JLABs @ Shanghai, which is a high recognition for GeneQuantum Healthcare. By leveraging JLABS 'extensive network and resources, we will accelerate collaborative innovation, enabling international and domestic development of novel drug conjugates, and bringing more excellent drug conjugates to patients around the world. In addition, we will further deepen collaborations with pharmaceutical & biotech companies, CROs and other enterprises, accelerate the global promotion and application of our innovative technology platform, empower the development of next-generation drug conjugates, and promote the intelligent and digital upgrading of the entire industry.”

About GeneQuantum Healthcare

GeneQuantum, headquartered in China, is a global leader in the ADC field, distinguished for its advancement of enzymatic site-specific conjugation technologies. GQ’s pioneering technologies, iLDC and iGDC, serve as the foundation of a comprehensive ADC drug development platform, spanning from the initial design to seamless commercial production. The technology offered by GQ provides numerous advantages, such as exceptional product homogeneity, elevated process quality, enhanced metabolic stability, and low commercialization costs. GQ remains steadfast in its commitment to delivering vital technical support, expediting global ADC drug development. 

For more information, please visit www.genequantum.com.